Ruti Aga's Six-Year Ban: The Forged Prescription Erased the Defence That Could Have Held

Thursday's Athletics Integrity Unit statement carried two numbers — two years, and four. Added, six. Ruti Aga, the 32-year-old Ethiopian marathoner, had been provisionally suspended since 10 September, and that same date now anchors a six-year ban. The headline detail is the forged prescription. The instructive detail sits behind it, in three separate verification failures: a clinic that does not exist, a 'doctor' who is a family member with no medical registration, and an 'old prescription pad' the clinic itself disowned. Three documents before the fall, and the paper was already late. Aga's record matters for understanding the moment this case was built on. The 2026 Tokyo Marathon title is hers, along with three second-place finishes at World Marathon Majors. My notebook carries a personal best of roughly 2:18:34 from Berlin 2026 and about 2:20:40 in Tokyo 2026 — figures worth re-checking against public results, because the statement itself gives no mark at all. This is the tier where an athlete earns serious money at the Majors and survives the gaps between them on Asian label races. The March half marathon in China was one of those gap races, and Aga won it. What the mark was, what the margin was, how deep the field ran — none of it is in the statement, so any form judgement would be invention. One solid performance fact survives: winning implies an elite international field and in-competition testing. Everything else walked out of the race with the sample. The substance at the centre of this case is methylprednisolone, and a technical correction is necessary here because most coverage skips it. Calling it a 'prohibited steroid' is imprecise to the point of distortion. It is a glucocorticoid — class S9 on the WADA Prohibited List — not an anabolic steroid, which sits in S1. Under the current List, S9 glucocorticoids are prohibited in-competition only, and only by injection, oral or rectal routes. Intra-articular injection for knee synovitis is standard sports-medicine practice in distance runners. That distinction moves the entire legal centre of the case: the question is not whether a steroid was taken, but by which route and how many days before the gun. Road-race testing sharpens that question further. The in-competition window opens at 23:59 the day before the race, so an injection given days earlier can still be caught — and managing that window is the job of the athlete's medical team. Aga had a viable path: real records, a real clinic, a clear note of the injection date and route, and a therapeutic use exemption application where needed. In any version of that story, a defence existed. Then the prescription arrived and the defence closed. The two-plus-four arithmetic is itself a report. Two years for the presence violation sits in the band reserved for a specified substance where intent is not proven. Four years for tampering is the Code's standard sanction. The panel therefore declined the no-significant-fault mitigation that would have pulled the presence sanction below two years. The numbers say the document, not the drug, decided the outcome. And the document failed in three places. The clinic named on the pad did not exist. The person who wrote it was a family member with no medical registration. That person then explained the pad came from 'a former workplace', which the clinic flatly disowned. The four-year tampering charge came from statements made in an investigative interview, not from the paper alone. That detail matters: language and interpretation conditions in AIU interviews with Ethiopian athletes have been a recurring point of contention, and in cases like this the athlete's own account becomes the heaviest exhibit against her. An uncomfortable comparison follows. Six years landed for a substance with no proven endurance benefit. For a marathoner, a glucocorticoid is a tool against pain and swelling, not a tool for speed. Those who will hold this up as proof of AIU rigour and those who will read it as disproportionate enforcement against African road runners both hold half the truth. The severity attached to the paperwork, not the pharmacology — and that is the real shift. The disproportionality argument runs through the same fact: the weight of the sanction rests on what the athlete did to defend herself, not on what she took. The larger signal is that the investigative frontier has moved. The old question was what the sample contained. The new question is what the paper says, who wrote it, and whether that clinic was open that week. China's label-race circuit is becoming the centre of that shift, because three things meet there at once: large appearance-fee budgets, deep East African elite fields, and AIU presence. The appearance-fee economy and the testing economy now collide in the same races. And the knee that started all of this remains unresolved. A marathoner's income is tied to availability; stopping for an injury costs appearance fees, sponsors and ranking simultaneously. The pressure to mask pain is real, and a glucocorticoid is the cheapest, most available answer to it. What this case shows is an athlete operating without a credentialed team physician, reaching for a document that the first verification would break. That does not soften the offence. It locates where the offence came from. What to watch now. The CAS appeal window typically runs about 21 days from the reasoned decision, and a tampering finding built on documents is hard to overturn. The statement does not say whether the March result and its prize money will be annulled, though disqualification of the competition where the sample was collected is standard AIU practice, so assume it. The largest question is the one the statement leaves untouched: who advised on that prescription, and was the entourage investigated. Until that is answered, this file reads less like one athlete's error and more like a record of a system's empty space.